Surgical Menopause: What to Expect After Hysterectomy or Oophorectomy

Hormone therapy for menopause is rife with confusion, fear, misunderstanding, and outright misinformation. Even doctors — who are often relying on long-debunked research — can be at a loss to help women make educated choices for their health and well-being.

Surgical menopause isn’t a slower, gentler version of the natural transition. When both ovaries are removed, estrogen and testosterone production drops within hours rather than over years, and the symptoms that follow are typically more intense, more abrupt, and more likely to need treatment than in spontaneous menopause.

This guide explains what surgical menopause actually is, how it differs from natural menopause and from hysterectomy alone, what to expect in the days and weeks after surgery, and how the Menopause Society and other major guidelines frame hormone therapy decisions for women in this situation — including women whose oophorectomy was performed for cancer risk reduction.

Key takeaways

Surgical menopause occurs when both ovaries are removed (bilateral oophorectomy). Hot flushes, sleep disruption, vaginal dryness, and mood changes can begin within 24 to 72 hours of surgery.

A hysterectomy that preserves the ovaries does not cause surgical menopause directly, though it can shift the timing of natural menopause earlier by one to four years.

Surgical menopause symptoms are typically more severe than those in natural menopause because the hormonal drop is abrupt rather than gradual.

For women under 45 without contraindications, The Menopause Society and other major bodies recommend systemic hormone therapy until at least the average age of natural menopause to mitigate long-term cardiovascular, bone, and cognitive risks.

Women whose oophorectomy was performed for BRCA1/BRCA2-related risk reduction can usually take hormone therapy until age 45 to 51 without measurably increasing breast cancer risk, per current society guidance — though this decision belongs in conversation with a clinician who knows the full picture.

The short answer: what surgical menopause is

Surgical menopause is the abrupt loss of ovarian function caused by removing both ovaries (bilateral oophorectomy). Unlike natural menopause, which unfolds over years as ovarian reserve declines, surgical menopause causes estrogen, progesterone, and testosterone levels to drop within hours. Symptoms typically begin within days and often peak in the first few months.

The age at which the surgery happens matters more than almost any other factor. A 35-year-old who has both ovaries removed for a BRCA mutation faces a different clinical and hormonal trajectory than a 53-year-old whose ovaries are removed during cancer treatment. The first will likely benefit from years of hormone therapy. The second is usually managed similarly to natural postmenopause.

What counts as surgical menopause — and what doesn’t

There are three pelvic surgeries that get confused in conversation about menopause, and the distinctions matter clinically.

Bilateral oophorectomy — this causes surgical menopause

When hormones are robust, your genitals thrive — they're thick, they lubricate, they're healthy, they're acidic, and the microbiome is on point. When hormone levels start to drop, you start getting urinary frequency or urgency, itching, burning, and dryness — and you may start to have pain with sex. And the craziest thing is that Genitourinary Syndrome of Menopause was only coined in 2014.

Removal of both ovaries causes immediate, complete loss of ovarian hormone production. This is what surgical menopause refers to. It can happen on its own (for ovarian cancer, BRCA risk reduction, or severe endometriosis) or alongside a hysterectomy.

Hysterectomy with ovarian conservation — this does not cause surgical menopause directly

Removing the uterus while leaving the ovaries in place doesn’t cause immediate menopause. Your ovaries continue producing hormones, and you’ll go through natural menopause when they eventually stop. The complication is that the average woman who has had her uterus removed reaches menopause one to four years earlier than she otherwise would have, likely due to changes in ovarian blood supply. You also lose menstrual bleeding as a marker, which makes it harder to know when you’re in perimenopause. Symptoms — cycle-independent ones like hot flushes, sleep changes, and mood shifts — become the only signal.

Unilateral oophorectomy — typically doesn’t cause surgical menopause

Removal of one ovary leaves the other one functional. Most women continue ovulating and menstruating normally, though there is some evidence of slightly earlier natural menopause in this group as well.

If you’re not sure which surgery you had, the operative report should specify. The terminology in informal conversation is loose: “hysterectomy” gets used to describe everything from cervix-only procedures to hysterectomy-plus-bilateral-oophorectomy. The pathology and operative reports are the source of truth.

How surgical menopause differs from natural menopause

The biology of an abrupt hormonal drop produces a different clinical picture than the gradual decline of natural menopause. Three differences matter most.

Symptoms come on faster and feel more intense. In natural menopause, the body adapts to declining estrogen over years. In surgical menopause, the system has hours to days. Hot flushes are typically more frequent and more severe. Vaginal dryness can appear within weeks. Sleep disruption often shows up before you’ve left the hospital. The Menopause Society and IMS both note that vasomotor symptoms in surgical menopause are reliably more disruptive than in matched cases of natural menopause.

The cardiovascular and bone risk profile starts earlier. Estrogen has protective effects on bone density, lipid metabolism, and vascular function. When ovaries are removed in a younger woman, the body loses that protection years or decades earlier than it would in natural menopause. The American Heart Association’s 2020 Scientific Statement on the menopause transition and cardiovascular disease risk emphasizes that early loss of ovarian function — surgical or otherwise — is independently associated with cardiovascular risk and warrants attention regardless of symptom severity.

Genitourinary symptoms appear earlier and progress faster. Vaginal dryness, painful intercourse, and urinary symptoms — collectively called genitourinary syndrome of menopause — typically take years to develop in natural menopause. In surgical menopause, they can appear within months. For more on this category of symptoms, see our guide to painful sex after menopause.

What to expect in the first weeks and months

Recovery from the surgery itself dominates the first week or two. Once you’re past the surgical recovery — typically two to six weeks depending on the approach — the menopausal symptoms take over as the primary issue.

Days 1 to 7. Surgical pain and recovery dominate. Some women notice hot flushes within 24 to 72 hours; others don’t begin until the second or third week. Sleep is typically poor from a combination of post-operative discomfort, medications, and the early hormonal drop.

Weeks 2 to 6. Hot flushes and night sweats often peak in this window. Mood symptoms — irritability, anxiety, low mood, tearfulness — frequently appear. Vaginal dryness can begin, though it’s often masked by surgical site healing in the short term. Cognitive symptoms (word-finding lapses, slower processing, difficulty concentrating) are common and unsettling.

Months 2 to 6. For women not on hormone therapy, symptoms typically remain intense through this period. For women started on systemic hormone therapy at or near the time of surgery, symptoms are often substantially controlled within a few weeks of starting treatment.

Months 6 to 12. Without treatment, vasomotor symptoms often plateau but remain present. Joint aches and muscle stiffness become more noticeable. Vaginal and urinary symptoms become more prominent. Some women report a slow, partial adaptation; others find symptoms steady or worsening.

If you’re tracking your symptoms day by day in this period, patterns emerge that can shape treatment decisions — frequency and timing of hot flushes, sleep disruption, mood, and energy. That data also helps a clinician calibrate hormone therapy dose and route faster than guesswork.

Hormone therapy after surgical menopause

There's an interesting perception that women's health is not real medicine — like, say, studying cancer or strokes — that periods and menopause are not as worthy of medical attention or research funding. Even in terms of insurance coverage, women's health has always been some of the poorest.

For most women who experience surgical menopause, particularly under age 45, the question isn’t whether hormone therapy is reasonable but whether there’s a specific reason not to use it. Major guidelines are notably consistent on this point.

The Menopause Society’s 2022 Hormone Therapy Position Statement explicitly notes that women with premature or early menopause — including surgical menopause before age 45 — should be offered hormone therapy at least until the average age of natural menopause (around 51) in the absence of contraindications. The rationale is risk mitigation: cardiovascular, bone, cognitive, and genitourinary risks all rise meaningfully with years of unopposed estrogen deficiency, and the benefit-risk math in younger women looks very different from the math used to evaluate hormone therapy in older postmenopausal women.

NICE Guideline NG23 (updated November 2024) makes the same point in stronger language, recommending that women with early menopause or POI be offered hormone therapy until at least age 51 and that the conversation framing should make clear this is replacement of normal physiologic hormones rather than supplementation.

Estrogen-only versus estrogen-plus-progestogen

The therapy regimen depends on whether you still have a uterus.

If the uterus was also removed (hysterectomy plus bilateral oophorectomy), estrogen-only therapy is typically used. Without a uterus, there’s no endometrium to protect from estrogen stimulation, which means progestogen isn’t needed and avoids the small added breast cancer risk associated with combined therapy in the Women’s Health Initiative.

If the uterus was preserved (bilateral oophorectomy without hysterectomy, which is less common), combined estrogen-plus-progestogen therapy is needed to prevent endometrial hyperplasia.

Routes of delivery — oral, transdermal patch, gel, spray, vaginal ring — each have their own pros and cons. Transdermal estrogen is often preferred when there are concerns about venous thromboembolism risk, since it bypasses first-pass hepatic metabolism. Decisions about formulation, dose, and route belong with a clinician who knows your full history.

Testosterone

Bilateral oophorectomy reduces circulating testosterone by roughly 50%, since the ovaries contribute meaningfully to testosterone production even after menopause. Some women experience marked decreases in libido, energy, and sense of well-being following surgical menopause that estrogen therapy alone doesn’t fully address. The Global Consensus Position Statement on the use of testosterone therapy for women recognizes hypoactive sexual desire disorder as the primary evidence-supported indication. Testosterone is not FDA-approved for women in the United States, which means any prescription is off-label and requires a clinician comfortable with the evidence and monitoring requirements.

Special situation: oophorectomy for BRCA1/BRCA2 risk reduction

Women carrying pathogenic BRCA1 or BRCA2 variants are often advised to consider risk-reducing bilateral salpingo-oophorectomy (RRSO) between ages 35 and 45 to reduce ovarian and breast cancer risk. The decision is typically time-pressured and emotionally loaded, and it often happens during years when natural menopause is still a long way off.

The historical concern was that hormone therapy after RRSO might undermine the breast cancer risk reduction the surgery was supposed to provide. Current evidence and society guidance no longer support this view in the strong form it once held. Multiple observational studies have shown that short-term hormone therapy after RRSO in BRCA1 mutation carriers does not measurably increase breast cancer risk in the years observed. Both the Menopause Society 2022 Position Statement and the American College of Obstetricians and Gynecologists Practice Bulletin on hereditary cancer syndromes support short-term hormone therapy after RRSO for symptom management in women without a personal history of breast cancer, particularly when surgery is performed at a young age.

For BRCA mutation carriers who have already had breast cancer, the calculation changes. Systemic hormone therapy is typically avoided, and management focuses on non-hormonal options for vasomotor symptoms and on low-dose vaginal therapy for genitourinary symptoms (the latter often acceptable in consultation with the treating oncologist). For more detail on non-hormonal treatment for women in active or post-cancer care, see our guide to tamoxifen side effects.

Non-hormonal options

Hormone therapy isn’t appropriate or wanted for every woman in surgical menopause. The non-hormonal options most supported by evidence are the same ones used in natural menopause, with the caveat that they’re often less effective in the more intense symptom picture of surgical menopause.

SSRIs and SNRIs. Paroxetine, escitalopram, venlafaxine, and desvenlafaxine all have evidence for reducing hot flush frequency and severity, typically by 40 to 65 percent in trials — modest compared to hormone therapy’s 75 percent but meaningful for women who can’t use hormones.

Gabapentin. Useful for night sweats specifically because the dosing window can be timed to bedtime. Side effects include sedation and dizziness; many women find the dosing flexibility helpful for mixed sleep and VMS issues.

Fezolinetant (Veozah). The first FDA-approved neurokinin B receptor antagonist, approved in 2023 based on the SKYLIGHT trials. It targets the hypothalamic mechanism driving hot flushes directly and is non-hormonal. Our Veozah explainer covers what to expect from this option, including the liver monitoring requirements.

Cognitive behavioral therapy. The MENOS 1 and MENOS 2 trials demonstrated meaningful reductions in the bother of hot flushes — not the frequency, but how disruptive they feel — through structured CBT.

Vaginal estrogen for GSM. Low-dose vaginal estrogen achieves serum levels comparable to postmenopausal baseline and is considered safe for most women, including many with prior breast cancer when discussed with oncology. For depth on this, see Is vaginal estrogen safe?.

What this means for you

If you’re approaching surgery or recently had it: the most consequential decision-point is whether and when to start hormone therapy. For women under 45 without contraindications, the evidence-based default position from every major society is to use systemic hormone therapy until at least the average age of natural menopause. The question is rarely whether to treat — it’s the regimen, dose, and route.

If you’re older than 50 at the time of surgery, the framework looks more like natural postmenopause: hormone therapy is reasonable if symptoms are significant and there are no contraindications, but the urgency is lower because the years of estrogen deficiency you’d otherwise face are also fewer.

If you have a personal or strong family history of breast cancer, the conversation becomes more nuanced and benefits from a clinician familiar with both menopause management and cancer survivorship. Non-hormonal options are often the default, and they can be more effective than women are sometimes led to believe.

Tracking what you actually experience day to day — symptom frequency, sleep, mood, what triggers flares — gives both you and your clinician something concrete to calibrate against. That’s true in any menopause context, but it matters more in surgical menopause because the symptom intensity moves faster and the treatment adjustments tend to come quicker.

When to talk to your doctor

Reach out to a clinician — ideally one with menopause expertise — if:

You’re scheduled for bilateral oophorectomy and haven’t yet discussed post-operative hormone therapy

You’re within the first three months after surgery and symptoms are interfering with sleep, work, or relationships

You’re more than six months out, not on hormone therapy, and symptoms aren’t improving

You’re on hormone therapy and symptoms are inadequately controlled at your current dose or route

You’re having vaginal dryness, painful intercourse, or recurrent urinary symptoms

You’re a BRCA mutation carrier post-RRSO and haven’t reviewed the current evidence on short-term hormone therapy with someone current on the literature

You have a history of breast cancer and need help managing symptoms without systemic estrogen

For a structured approach to that conversation, see our guide to talking to your doctor about menopause.

Frequently asked questions

Sources

The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. (Surgical menopause and early menopause HT recommendations.)

National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024. (Early menopause and surgical menopause HT recommendations.)

Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926-937.

El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532.

Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of testosterone therapy for women. Journal of Clinical Endocrinology & Metabolism. 2019;104(10):4660-4666.

American College of Obstetricians and Gynecologists. Hereditary Cancer Syndromes and Risk Assessment (Practice Bulletin 182). 2017 (reaffirmed).

The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.

Disclaimer

This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Prescription medications referenced in this article — including systemic hormone therapy, vaginal estrogen, testosterone (off-label in the United States for women), SSRIs and SNRIs, gabapentin, and fezolinetant — require evaluation by a clinician and are not appropriate for everyone. Decisions about hormone therapy after risk-reducing oophorectomy or in the setting of a personal cancer history should be made with a clinician familiar with the current evidence.